Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clinical Decision-Making | 4 | 2026 | 364 | 1.840 |
Why?
|
| Internal Medicine | 2 | 2025 | 279 | 1.410 |
Why?
|
| Point-of-Care Systems | 2 | 2025 | 189 | 1.270 |
Why?
|
| Likelihood Functions | 2 | 2026 | 138 | 0.810 |
Why?
|
| Infection Control | 1 | 2025 | 173 | 0.800 |
Why?
|
| Air Pollution, Indoor | 1 | 2025 | 171 | 0.780 |
Why?
|
| Internship and Residency | 2 | 2025 | 1269 | 0.760 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2020 | 107 | 0.710 |
Why?
|
| Respiratory Tract Infections | 1 | 2025 | 396 | 0.660 |
Why?
|
| Mitral Valve Stenosis | 1 | 2019 | 20 | 0.580 |
Why?
|
| Probability | 1 | 2020 | 308 | 0.580 |
Why?
|
| Endocarditis, Bacterial | 1 | 2019 | 46 | 0.560 |
Why?
|
| Echocardiography, Doppler | 1 | 2019 | 115 | 0.550 |
Why?
|
| Research Design | 1 | 2024 | 1139 | 0.550 |
Why?
|
| Curriculum | 1 | 2025 | 1074 | 0.550 |
Why?
|
| Data Interpretation, Statistical | 1 | 2020 | 368 | 0.540 |
Why?
|
| Dabigatran | 1 | 2018 | 30 | 0.540 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 268 | 0.540 |
Why?
|
| Research Personnel | 1 | 2020 | 185 | 0.540 |
Why?
|
| ROC Curve | 1 | 2019 | 618 | 0.510 |
Why?
|
| Heart Failure | 3 | 2026 | 2326 | 0.390 |
Why?
|
| Biomedical Research | 1 | 2020 | 719 | 0.390 |
Why?
|
| Stroke | 2 | 2019 | 1271 | 0.380 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 558 | 0.340 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 1925 | 0.340 |
Why?
|
| Clinical Competence | 3 | 2025 | 1247 | 0.330 |
Why?
|
| Hospitalists | 2 | 2024 | 267 | 0.300 |
Why?
|
| Bayes Theorem | 2 | 2022 | 421 | 0.290 |
Why?
|
| Patient Safety | 2 | 2024 | 356 | 0.290 |
Why?
|
| Humans | 24 | 2026 | 145763 | 0.250 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2016 | 43 | 0.230 |
Why?
|
| Air Microbiology | 1 | 2025 | 37 | 0.220 |
Why?
|
| Pulmonary Embolism | 1 | 2026 | 241 | 0.200 |
Why?
|
| Delphi Technique | 1 | 2025 | 333 | 0.200 |
Why?
|
| Academic Medical Centers | 2 | 2024 | 554 | 0.200 |
Why?
|
| Psychological Tests | 1 | 2024 | 130 | 0.190 |
Why?
|
| Aortic Valve | 2 | 2016 | 364 | 0.190 |
Why?
|
| Canada | 1 | 2024 | 432 | 0.190 |
Why?
|
| Ventricular Function, Left | 2 | 2016 | 544 | 0.180 |
Why?
|
| Ultrasonography | 1 | 2025 | 788 | 0.170 |
Why?
|
| Problem Solving | 1 | 2022 | 156 | 0.170 |
Why?
|
| Patient Satisfaction | 1 | 2024 | 712 | 0.160 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 65 | 0.160 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2020 | 17 | 0.150 |
Why?
|
| Furosemide | 1 | 2020 | 37 | 0.150 |
Why?
|
| Critical Pathways | 1 | 2021 | 109 | 0.150 |
Why?
|
| Receptors, Atrial Natriuretic Factor | 1 | 2019 | 3 | 0.150 |
Why?
|
| Physician-Patient Relations | 1 | 2024 | 588 | 0.150 |
Why?
|
| Troponin | 1 | 2019 | 50 | 0.150 |
Why?
|
| Streptococcus mutans | 1 | 2019 | 8 | 0.150 |
Why?
|
| Cryoglobulins | 1 | 2018 | 5 | 0.140 |
Why?
|
| Glomerulonephritis | 1 | 2019 | 44 | 0.140 |
Why?
|
| Mycoplasma Infections | 1 | 2018 | 17 | 0.140 |
Why?
|
| Conservative Treatment | 1 | 2019 | 45 | 0.140 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2019 | 58 | 0.140 |
Why?
|
| Multimorbidity | 1 | 2019 | 65 | 0.140 |
Why?
|
| Male | 11 | 2026 | 73003 | 0.140 |
Why?
|
| Rheumatic Diseases | 1 | 2019 | 98 | 0.130 |
Why?
|
| United States | 2 | 2025 | 16123 | 0.130 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 287 | 0.120 |
Why?
|
| Inpatients | 1 | 2021 | 553 | 0.120 |
Why?
|
| Educational Measurement | 1 | 2019 | 326 | 0.120 |
Why?
|
| Streptococcal Infections | 1 | 2019 | 171 | 0.120 |
Why?
|
| Warfarin | 1 | 2018 | 179 | 0.120 |
Why?
|
| Hepatitis C | 1 | 2019 | 256 | 0.120 |
Why?
|
| Middle Aged | 6 | 2021 | 36302 | 0.120 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 297 | 0.110 |
Why?
|
| Risk Assessment | 3 | 2021 | 3752 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 5922 | 0.110 |
Why?
|
| Adult | 6 | 2026 | 40872 | 0.110 |
Why?
|
| Arterio-Arterial Fistula | 1 | 2014 | 4 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 2000 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2022 | 11793 | 0.100 |
Why?
|
| Coronary Aneurysm | 1 | 2014 | 17 | 0.100 |
Why?
|
| Patient Discharge | 1 | 2021 | 995 | 0.100 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2014 | 38 | 0.100 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2016 | 154 | 0.100 |
Why?
|
| Ventricular Remodeling | 1 | 2016 | 278 | 0.100 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2016 | 198 | 0.100 |
Why?
|
| Incidental Findings | 1 | 2014 | 81 | 0.100 |
Why?
|
| Aortic Valve Stenosis | 1 | 2016 | 256 | 0.090 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2016 | 394 | 0.090 |
Why?
|
| Heart Block | 1 | 2012 | 41 | 0.090 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2012 | 49 | 0.090 |
Why?
|
| Cardiac Catheterization | 1 | 2016 | 559 | 0.090 |
Why?
|
| Anticoagulants | 1 | 2018 | 748 | 0.090 |
Why?
|
| Heart Conduction System | 1 | 2012 | 96 | 0.090 |
Why?
|
| Mitral Valve | 1 | 2012 | 95 | 0.090 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2018 | 549 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 1211 | 0.090 |
Why?
|
| Female | 8 | 2026 | 79035 | 0.080 |
Why?
|
| Heart Valve Diseases | 1 | 2012 | 151 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 6085 | 0.080 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 2383 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5428 | 0.070 |
Why?
|
| Catheter Ablation | 1 | 2012 | 355 | 0.070 |
Why?
|
| Aged | 5 | 2020 | 26215 | 0.070 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2012 | 611 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 971 | 0.050 |
Why?
|
| Inservice Training | 1 | 2024 | 118 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 1330 | 0.050 |
Why?
|
| Time Factors | 3 | 2016 | 7133 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2020 | 360 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2022 | 666 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2021 | 280 | 0.040 |
Why?
|
| Self Report | 1 | 2024 | 876 | 0.040 |
Why?
|
| Vibration | 1 | 2019 | 70 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 8346 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 507 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 2933 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2019 | 17325 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2022 | 2064 | 0.030 |
Why?
|
| Cold Temperature | 1 | 2018 | 206 | 0.030 |
Why?
|
| Fibrosis | 1 | 2019 | 561 | 0.030 |
Why?
|
| Risk Factors | 3 | 2016 | 10917 | 0.030 |
Why?
|
| Diastole | 1 | 2016 | 146 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1662 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 740 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2021 | 772 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 2016 | 129 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 3346 | 0.020 |
Why?
|
| Voltage-Sensitive Dye Imaging | 1 | 2012 | 4 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2016 | 655 | 0.020 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2012 | 82 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2014 | 328 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2016 | 716 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 528 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 3416 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 1850 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 1491 | 0.020 |
Why?
|
| Action Potentials | 1 | 2012 | 502 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 1139 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2012 | 668 | 0.020 |
Why?
|
| Hospitalization | 1 | 2019 | 2460 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 2123 | 0.020 |
Why?
|
| Biomarkers | 1 | 2019 | 4302 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2770 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3915 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 22573 | 0.010 |
Why?
|